TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

Company Overview

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $0.03 to $0.05
• 50-Day Range: $0.02 to $0.08
• 52-Week Range: $0.00 to $14.75
• Volume: 23,886 shs
• Average Volume: 120,908 shs
• Market Capitalization: $109.80 thousand
• P/E Ratio: 0.01
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TCON Stock Analysis - Frequently Asked Questions

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) issued its quarterly earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.13. The biopharmaceutical company had revenue of $0.10 million for the quarter.

When did TRACON Pharmaceuticals' stock split?

TRACON Pharmaceuticals's stock reverse split on the morning of Wednesday, April 10th 2024.The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did TRACON Pharmaceuticals IPO?

TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Advanced Micro Devices (AMD), OPKO Health (OPK), Taiwan Semiconductor Manufacturing (TSM) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/14/2024
• Today: 7/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCON
• CIK: 1394319
• Web: www.traconpharma.com
• Phone: (858) 550-0780
• Fax: 858-550-0786
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $3.73
• Trailing P/E Ratio: 0.01
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.59 million
• Net Margins: N/A
• Pretax Margin: 145.93%
• Return on Equity: -237.65%
• Return on Assets: 57.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.66
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $12.05 million
• Price / Sales: 0.01
• Cash Flow: $1.61 per share
• Price / Cash Flow: 0.02
• Book Value: ($0.37) per share
• Price / Book: -0.09

Miscellaneous

• Outstanding Shares: 3,410,000
• Free Float: 3,228,000
• Market Cap: $109.80 thousand
• Optionable: No Data
• Beta: 1.37